T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

Adoptive T Cell Therapy Applications

CAR-T Cell Toxicity and Safety Profiles

T-Cell Metabolism, Immunodeficiency and Human Disease

Precision immunotherapy for TRBC2-positive T-cell malignancies

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors.

22 Dec 2025

Engineered extracellular vesicles enable antigen-specific regulatory T cell induction

A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has developed a new class of engineered extracellular vesicles (EVs) capable of inducing antigen-specific regulatory T cells (Tregs), the immune cells that play a central role in suppressing excessive immune responses.

22 Dec 2025

Hidden kinase state enables rapid and repeated protein phosphorylation

Scientists at St. Jude Children's Research Hospital have characterized a hidden intermediate state at the center of Src kinase function. This hidden state allows the kinase to repeatedly modify its target, without needing to release and reattach to the target each time.

19 Dec 2025

Autophagy steers T cell fate during immune division

Researchers at the Max Delbrück Center have found that a cellular housekeeping mechanism called autophagy plays a major role in ensuring that T stem cells undergo normal cell division.

19 Dec 2025

Novel cryo-EM findings could revolutionize T cell immunotherapy design

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack dangerous cells. Yet a full understanding of how they actually work has eluded researchers.

16 Dec 2025

Early relapse predicts poor survival in mature nodal T-cell lymphoma

Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify high-risk patients or tailor treatment strategies, so most patients receive similar care despite differences in disease characteristics and outcomes.

12 Dec 2025

Review highlights emerging role of tumor MHC-II in shaping cancer immunotherapy outcomes

Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.

11 Dec 2025

Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of the phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

11 Dec 2025

Patients receiving T-cell redirecting therapies can safely be monitored at home

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects.

9 Dec 2025

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL).

8 Dec 2025

Powerful prognostic marker could enable early identification of high-risk cancer patients

Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate.

8 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians at Fox Chase Cancer Center and Temple Health.

8 Dec 2025

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

8 Dec 2025

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, are associated with high rates of death unrelated to cancer relapse-primarily infection-and may be avoidable.

8 Dec 2025

Engineered herpes virus activates potent immune responses against glioblastoma

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

4 Dec 2025

Generative AI aids discovery of ISM3830's novel scaffold

Casitas B-lineage lymphoma-b (CBLB) is an E3 ubiquitin–protein ligase that functions as an intracellular checkpoint and master negative regulator of T‑cell and natural killer (NK) cell activation, playing a central role in modulating T-cell activation and immune tolerance, and its inhibition enhances T cells and NK cells function, also provides a strategy for the function restoration of exhausted T cells.

1 Dec 2025

Breakthrough immunotherapy approved for treatment of adults with aggressive blood cancer

Adult patients with an aggressive form of leukemia will be able to receive a breakthrough immunotherapy, which was invented by UCL researchers, on the NHS within weeks following approval for use by the National Institute for Health and Care Excellence (NICE).

27 Nov 2025

New research questions reliability of macaque models for TIGIT-targeted cancer treatments

A new study published in the Journal of Biological Chemistry from UC Davis Comprehensive Cancer Center finds that TIGIT, an immune checkpoint receptor targeted by cancer immunotherapy drugs, triggers a different response in rhesus macaques compared to humans.

24 Nov 2025

Study introduces cost-effective approach to analyze entire T-cell repertoire

Studying T cells, the immune cells most responsible for responding to infections and cancers, just received a significant boost in the form of a new technique from St. Jude Children's Research Hospital.

24 Nov 2025

1
2
3
4
...
2911
Next

T Cell

Overview

Adoptive T Cell Therapy Applications

CAR-T Cell Toxicity and Safety Profiles

T-Cell Metabolism, Immunodeficiency and Human Disease

Latest T Cell News and Research

Precision immunotherapy for TRBC2-positive T-cell malignancies

Engineered extracellular vesicles enable antigen-specific regulatory T cell induction

Hidden kinase state enables rapid and repeated protein phosphorylation

Autophagy steers T cell fate during immune division

Novel cryo-EM findings could revolutionize T cell immunotherapy design

Early relapse predicts poor survival in mature nodal T-cell lymphoma

Review highlights emerging role of tumor MHC-II in shaping cancer immunotherapy outcomes

Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer

Patients receiving T-cell redirecting therapies can safely be monitored at home

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Powerful prognostic marker could enable early identification of high-risk cancer patients

Combination therapy may boost survival for people with aggressive lymphoma

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

Engineered herpes virus activates potent immune responses against glioblastoma

Generative AI aids discovery of ISM3830's novel scaffold

Breakthrough immunotherapy approved for treatment of adults with aggressive blood cancer

New research questions reliability of macaque models for TIGIT-targeted cancer treatments

Study introduces cost-effective approach to analyze entire T-cell repertoire

Immunology eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

T Cell

Overview

Latest T Cell News and Research

Immunology eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in